

OncoTherapy Science, Inc.

March 5, 2018

Announcement of the progress of Phase III clinical study
of the cancer-specific peptide vaccine S-588410

OncoTherapy Science, Inc. (President & CEO: Kazuo Yamamoto ; hereinafter, “OncoTherapy”) announces that patient enrollment has been completed in Phase III clinical study of the cancer-specific peptide vaccine S-588410 for esophageal cancer which OncoTherapy has out-licensed to Shionogi.